Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: Prospective analysis from the population-based Monitoring of Trends and determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg study and experimental data

Clinical Chemistry

Volumn 53, Issue 4, 2007, Pages 693-701

  Maas, Renke ^a   Schulze, Friedrich ^a   Baumert, Jens ^b   Löwel, Hannelore ^b   Hamraz, Khatera ^a   Schwedhelm, Edzard ^a   Koenig, Wolfgang ^c   Böger, Rainer H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYLARGININASE; N(G),N(G) DIMETHYLARGININE; TOBACCO SMOKE;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONFOUNDING VARIABLE; CONTROLLED STUDY; CORONARY RISK; FATALITY; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREDICTION; PROSPECTIVE STUDY; SMOKING; SUDDEN DEATH; TANDEM MASS SPECTROMETRY;

ADULT; AGED; ARGININE; CASE-CONTROL STUDIES; CELL LINE; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NITRIC OXIDE SYNTHASE; PLASMA; PROSPECTIVE STUDIES; RISK; SMOKING;

NICOTIANA TABACUM;

EID: 34147194549     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.081893     Document Type: Article

References (38)

1. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004;24:1023-30.
2. Böger RH. When the endothelium cannot say 'NO' anymore. ADMA, an endogenous inhibitor of NO synthase, promotes cardiovascular disease [Editorial]. Eur Heart J 2003;24:1901-2.
3. Tsikas D, Rode I, Becker T, Nashan B, Klempnauer J, Frölich JC. Elevated plasma and urine levels of ADMA and 15(S)-8-iso-PGF2alpha in end-stage liver disease. Hepatology 2003;38:1063-4.
4. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, et al. Endogenous nitric oxide synthase inhibitor, a novel marker of atherosclerosis. Circulation 1999;99:1141-6.
5. Kielstein JT, Böger RH, Bode-Böger SM, Frölich JC, Haller H, Ritz E, et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002;13:170-6.
6. Stühlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002;287:1420-6.
7. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001;358:2127-8.
8. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 2003;24:1912-9.
9. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005;97:e53-9.
10. Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS, et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 2002;13:490-6.
11. Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113-7.
12. Nijveldt RJ, Teerlink T, Van Der Hoven B, Siroen MP, Kuik DJ, Rauwerda JA, et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 2003;22:23-30.
13. WHO-MONICA Project Principal Investigators. The World Health Organization MONICA Project (Monitoring Trends and Determinants in Cardiovascular Disease): a major international collaboration. J Clin Epidemiol 1988;41:105-14.
14. WHO MONICA Project. WHO MONICA project: objectives and design. Int J Epidemiol 1989;18(Suppl 1):29-37.
15. Loewel H, Lewis M, Hoermann A, Keil U. Case finding, data quality aspects and comparability of myocardial infarction registers: results of a south German register study. J Clin Epidemiol 1991;44:249-60.
16. Hense HW, Filipiak B, Döring A, Stieber J, Liese A, Keil U. Ten-year trends of cardiovascular risk factors in the MONICA Augsburg region in southern Germany: results from 1984/1985, 1989/1990, and 1994/1995 surveys. CVD Prevention 1998;1:318-27.
17. Koenig W, Sund M, Döring A, Ernst E. Leisure-time physical activity but not work-related physical activity is associated with decreased plasma viscosity: results from a large population sample. Circulation 1997;95:335-41.
18. Edgell CJ, McDonald CC, Graham JB. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci U S A 1983;80:3734-7.
19. Hutchinson WL, Koenig W, Fröhlich M, Sund M, Lowe GD, Pepys MB. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem 2000;46:934-8.
20. Schwedhelm E, Tan-Andresen J, Maas R, Riederer U, Schulze F, Böger RH. Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem 2005;51:1268-71.
21. Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, Cooke JP, et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 2004;42:1377-83.
22. Levey AS, Greene T, Kusek JW, Beck GJ, Group MS. A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol 2000;11:A0828.
23. Kielstein JT, Peter C, Adams MC. Cigarettes and ADMA: the smoke hasn't cleared yet. Hypertension 2006;48:E20.
24. Eid HM, Arnesen H, Hjerkinn EM, Lyberg T, Seljeflot I. Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metabolism 2004;53:1574-9.
25. Maas R. Pharmacotherapies and their influence on asymmetric dimethylarginine (ADMA). Vasc Med 2005;10(Suppl 1):S49-57.
26. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999;343:209-14.
27. Murray-Rust J, Leiper J, McAlister M, Phelan J, Tilley S, Santa Maria J, et al. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol 2001;8:679-83. [Erratum in Nat Struct Biol 2001;8:818.]
28. Sydow K, Münzel T. ADMA and oxidative stress. Atheroscler Suppl 2003;4:41-51.
29. Fröhlich M, Sund M, Lowel H, Imhof A, Hoffmeister A, Koenig W. Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J 2003;24:1365-72.
30. Zoccali C, Maas R, Cutrupi S, Pizzini P, Finocchiaro P, Cambareri F, et al. Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections. Nephrol Dial Transplant 2006 [Epub ahead of print] doi:10.1093/ndt/gfl719.
31. Zhang WZ, Venardos K, Chin-Dusting J, Kaye DM. Adverse effects of cigarette smoke on NO bioavailability: role of arginine metabolism and oxidative stress. Hypertension 2006;48:278-85.
32. Jiang DJ, Jia SJ, Yan J, Zhou Z, Yuan Q, Li YJ. Involvement of DDAH/ADMA/NOS pathway in nicotine-induced endothelial dysfunction. Biochem Biophys Res Commun 2006;349:683-93.
33. Hamasaki H, Sato J, Masuda H, Tamaoki S, Isotani E, Obayashi S, et al. Effect of nicotine on the intimal hyperplasia after endothelial removal of the rabbit carotid artery. Gen Pharmacol 1997;28:653-9.
34. Jorgensen ED, Dozmorov I, Frank MB, Centola M, Albino AP. Global gene expression analysis of human bronchial epithelial cells treated with tobacco condensates. Cell Cycle 2004;3:1154-68.
35. Mallamaci F, Tripepi G, Cutrupi S, Malatino LS, Zoccali C. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int 2005;67:2330-7.
36. Kostourou V, Robinson SP, Whitley GS, Griffiths JR. Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumor angiogenesis assessed by susceptibility magnetic resonance imaging. Cancer Res 2003;63:4960-6.
37. Kostourou V, Robinson SP, Cartwright JE, Whitley GS. Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis. Br J Cancer 2002;87:673-80.
38. Kielstein JT, Impraim B, Simmel S, Bode-Böger SM, Tsikas D, Frölich JC, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004;109:172-7.